Physician profile
William Lance Garner
NPI 1740291517
$13,169.79
in general payments reported to CMS, 2019-2025
35 companies · $711 in 2025
The $711 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,610 · 2020: $688 · 2021: $1,511 · 2022: $1,637 · 2023: $1,601 · 2024: $412 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,724.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,709.38 | 2019-2023 | |
| Medtronic Vascular, INC. | $2,119.33 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $1,932.97 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $1,678.84 | 2019-2023 | Jeti, Jeti Peripheral Catheter, Coroflow |
| Novo Nordisk INC | $667.54 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $646.04 | 2019-2024 | Xarelto |
| Amgen INC. | $553.77 | 2019-2025 | Repatha, Repatha |
| Abiomed | $272.24 | 2019-2023 | Impella |
| Amarin Pharma, INC. | $271.15 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $267.86 | 2019-2025 | Lifevest |
| Medtronic, INC. | $258.61 | 2019-2021 | |
| Philips North America LLC | $209.82 | 2019-2022 | |
| Astellas Pharma US INC | $181.04 | 2020-2021 | |
| Cvrx, INC. | $151.09 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $138.85 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $132.97 | 2020 | |
| Siemens Medical Solutions USA, INC. | $111.15 | 2019 | |
| Esperion Therapeutics, INC. | $103.33 | 2020-2021 | |
| Kestra Medical Technology Services, INC. | $92.14 | 2022-2023 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $81.86 | 2019-2022 | |
| Chiesi USA, INC. | $76.75 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $76.71 | 2021-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $62.59 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $61.93 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.36 | 2019-2021 | |
| Baxter Healthcare | $58.18 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Boston Scientific Corporation | $33.18 | 2021 | |
| Veryan Medical Incorporated | $32.89 | 2022-2023 | Biomimics 3d Vascular Stent System |
| Kerecis Limited | $25.21 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Endologix LLC | $23.72 | 2025 | Torus Stent Graft System, Endocross Device |
| Braemar Manufacturing, LLC | $20.43 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.74 | 2019 | |
| Irhythm Technologies, INC. | $16.62 | 2020 | |
| Lundbeck LLC | $14.35 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.